News & Updates

Back to All News
Get Care

Lankenau Institute of Medical Research researcher chairs keynote at international chemical biology conference

Lankenau Medical Center November 19, 2015 Research News

Mel Reichman, PhD, a principal investigator at the Lankenau Institute for Medical Research (LIMR), was invited to serve as chairperson of the opening keynote session for the 2015 international joint conference of the European Chemical Biology Symposium (ECBS) and the International Chemical Biology Society (ICBS) held in Berlin, Germany, in October.

Dr. Reichman also gave the closing summary of the three-day conference that was attended by several hundred chemical biology researchers from around the globe. Additionally, he co-organized and co-chaired the session “Rising Stars in Chemical Biology,” an annual award session and ceremony for the three best presentations from young investigators in chemical biology worldwide.

Dr. Reichman founded and directs the LIMR Chemical Genomics Center, where he designed and built a patented automated repository and screening technology to help accelerate drug discovery. His current research focuses on developing and applying ultra-high throughput screening technologies to discover new drug synergies for treating diseases that have high unmet medical need, including neurodegeneration and diabetes complications.

He is an editor of several leading drug discovery journals, and serves as president and chairman of the board for the ICBS. Additionally, he has been named chair of the 2016 ECBS-ICBS conference to be held in Madison, Wisc.

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR’s mission is to improve human health and well-being. Faculty and staff are devoted to advancing innovative new approaches to formidable medical challenges, including cancer, cardiovascular disease, gastrointestinal disorders and autoimmune diseases, such as diabetes and arthritis. LIMR’s principal investigators conduct basic, preclinical and translational research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.